Abstract:Glycosylation of the SARS-CoV-2 spike (S) protein represents a key target for viral evolution because it affects both viral evasion and fitness. Successful variations in the glycan shield are difficult to achieve though, as protein glycosylation is also critical to folding and to structural stability. Within this framework, the identification of glycosylation sites that are structurally dispensable can provide insight into the evolutionary mechanisms of the shield and inform immune surveillance. In this work we show through over 45 μs of cumulative sampling from conventional and enhanced molecular dynamics (MD) simulations, how the structure of the immunodominant S receptor binding domain (RBD) is regulated by -glycosylation at N343 and how this glycan’s structural role changes from WHu-1, alpha (B.1.1.7), and beta (B.1.351), to the delta (B.1.617.2) and omicron (BA.1 and BA.2.86) variants. More specifically, we find that the amphipathic nature of the -glycan is instrumental to preserve the structural integrity of the RBD hydrophobic core and that loss of glycosylation at N343 triggers a specific and consistent conformational change. We show how this change allosterically regulates the conformation of the receptor binding motif (RBM) in the WHu-1, alpha and beta RBDs, but not in the delta and omicron variants, due to mutations that reinforce the RBD architecture. In support of these findings, we show that the binding of the RBD to monosialylated ganglioside co-receptors is highly dependent on N343 glycosylation in the WHu-1, but not in the delta RBD, and that affinity changes significantly across VoCs. Ultimately, the molecular and functional insight we provide in this work reinforces our understanding of the role of glycosylation in protein structure and function and it also allows us to identify the structural constraints within which the glycosylation site at N343 can become a hotspot for mutations in the SARS-CoV-2 S glycan shield.

Sugar Highs: Recent Notable Breakthroughs in Glycobiology

Glycosylation in the Tumor Immune Response: the Bitter Side of Sweetness

The Mechanism of Glycosylation in SARS-CoV-2 Infection and Application in Drug Development

The clinical impact of glycobiology: targeting selectins, Siglecs and mammalian glycans

Glycosylation is a key in SARS-CoV-2 infection

Glycosylation in SARS-CoV-2 variants: A path to infection and recovery

What comes next in glycobiology

Sweet systems: technologies for glycomic analysis and their integration into systems biology

Glycan Nanostructures of Human Coronaviruses

#GotGlycans: Role of N343 Glycosylation on the SARS-CoV-2 S RBD Structure and Co-Receptor Binding Across Variants of Concern

The glycosylation in SARS-CoV-2 and its receptor ACE2

Glycobiology of Cancer: Sugar Drives the Show

Exploring glycans as vital biological macromolecules: A comprehensive review of advancements in biomedical frontiers

How glycobiology can help us treat and beat the COVID-19 pandemic

The Research Progress in Protein Glycosylation Modification

Exploitation of glycosylation in enveloped virus pathobiology

The Glycosylation of Immune Checkpoints and Their Applications in Oncology

Glycosylation: mechanisms, biological functions and clinical implications

Site-specific glycosylation of SARS-CoV-2: Big challenges in mass spectrometry analysis

Glycoconjugates: Advances in modern medicines and human health